Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.

Revenue
+15.1%
EPS
+62.5%
Free cash flow
−9.63%

Quarter to September 2026, against a year earlier

24.11 28.41 −54.09%
Market cap
$1.9B
P/E
15.2×
Fwd P/E
45.2×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a

Veracyte, Inc. (VCYT) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Veracyte, Inc. (VCYT) trades at a P/E ratio of 15.2×. Over the past ten years it has ranged from 0.0× (December 2024) to 144× (January 2025); the current reading is higher than 84% of that period. That is below the Diagnostics & Research industry median of 34.5× and below the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 50.1× (59.50%)
FY2024 124× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 29.0× (29.00%)
Jun 2026 40.8× 40.55%
Mar 2026 29.0× (42.10%)
Dec 2025 50.1× (43.06%)
43 more quarters

Against its own ten years

Low 0.0× High 144×
Ten-year median 0.0×
Current reading's percentile 84

P/E ratio against peers

Company P/E ratio
WGS GeneDx Holdings Corp. compare n/m
RDNT RadNet, Inc. compare n/m
NEO NeoGenomics, Inc. compare n/m
GRAL GRAIL, Inc. compare n/m
ADPT Adaptive Biotechnologies Corporation compare n/m
VCYT Veracyte, Inc. 15.2×
SHC Sotera Health Company compare 26.3×
CDNA CareDx, Inc. compare 30.9×
BLLN BillionToOne, Inc. compare 88.7×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on VCYT